Particle.news

Intranasal mRNA Nose Drops Restore Memory and Boost Neuron Growth in Mice

If the result can be translated to people this noninvasive nasal route could deliver therapeutic proteins to the brain without surgery or injections.

Overview

  • University of Sydney researchers reported on Wednesday that lipid‑nanoparticle mRNA given as nasal drops instructed nasal cells to produce BDNF and restored learning and memory in aged mice.
  • Treated mice showed biological signs of repair: hippocampal markers of new neurons rose about 2.4 times and BDNF expression from the delivered mRNA was detectable for up to four days after dosing.
  • In the 5XFAD Alzheimer’s mouse model, twice‑weekly nasal dosing from an early disease stage preserved cognition at ages when untreated animals normally decline, even though brain amyloid plaque levels were unchanged.
  • The method uses mRNA‑LNP technology related to COVID‑19 vaccine platforms to turn the nose into a temporary protein factory that can reach the brain, but the results are strictly preclinical and human nasal anatomy and dosing must be tested.
  • Researchers say safety studies, formulation optimization and regulatory steps are needed before human trials could begin and they hope to move toward clinical testing in roughly two years if those steps succeed; the approach could complement, not replace, amyloid‑targeting treatments.